Serum subfatin levels as a potential biomarker for epileptic seizure diagnosis: A case-control study

This case-control study of 132 epilepsy patients and 131 controls found significantly lower serum subfatin levels in epilepsy patients compared to controls, with ROC analysis showing good diagnostic discriminatory power (AUC 0.84). The authors propose subfatin as a promising biomarker that may reflect neuroinflammatory processes in epileptogenesis, with potential diagnostic and prognostic utility.